Related Experiment Video
Updated: Jul 26, 2026
11:56
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
Published on: October 25, 2013
Daptomycin: a novel agent for Gram-positive infections
F P Tally1, M Zeckel, M M Wasilewski
1Cubist Pharmaceuticals, Inc., 24 Emily Street, Cambridge, MA 02139, USA. ftally@cubist.com
Expert Opinion on Investigational Drugs
|July 5, 2005
Summary
Daptomycin is a promising new antibiotic effective against resistant Gram-positive infections. Clinical trials show it is safe and effective for skin infections and bacteremia, with rare resistance development.
Area of Science:
- Infectious Diseases
- Pharmacology
- Microbiology
Background:
- Rising incidence of Gram-positive infections, including resistant strains like MRSA and VRE.
- Limited therapeutic options for these challenging infections.
- Need for novel antibiotics with broad-spectrum activity and favorable safety profiles.
Purpose of the Study:
- To evaluate the efficacy and safety of daptomycin, a novel lipopeptide antibiotic.
- To assess daptomycin's activity against various Gram-positive pathogens, including resistant strains.
- To determine daptomycin's pharmacokinetic and pharmacodynamic properties.
Main Methods:
- In vitro testing of bactericidal activity against clinically relevant Gram-positive bacteria.
- Pharmacokinetic studies to assess drug behavior in the body.
- Phase II clinical trials evaluating efficacy in skin/soft tissue infections and bacteremia.
- Safety assessments comparing adverse events to conventional therapies.
Main Results:
- Daptomycin demonstrated potent in vitro bactericidal activity against VRE, MRSA, GISA, CNS, and PRSP.
- Rapid, concentration-dependent killing and a prolonged post-antibiotic effect were observed.
- Phase II trials showed efficacy in skin/soft tissue infections and bacteremia with good safety profiles.
- Adverse events were uncommon and comparable to conventional treatments; muscle toxicity was minimal and reversible.
Conclusions:
- Daptomycin is a highly effective and safe antibiotic for Gram-positive infections, including those caused by resistant bacteria.
- Its rapid bactericidal action, favorable pharmacokinetics, and safety profile make it a valuable therapeutic option.
- Ongoing Phase II and III trials will further solidify its role in treating serious Gram-positive infections.
Related Concept Videos
01:15Determination of Multiple Dosing Parameters: Steady-State, Minimum and Maximum Concentrations
Gentamicin, an aminoglycoside antibiotic, is commonly administered via intermittent intravenous infusion to treat severe infections. An intermittent one-hour infusion of gentamicin, administered at eight-hour intervals, allows for precise control of plasma drug concentrations, minimizing toxicity while ensuring therapeutic efficacy. Pharmacokinetic principles govern the dynamics of plasma concentrations and can be mathematically described using specific equations.The plasma drug concentration...
01:20Estimation of k and VD of Aminoglycosides
Aminoglycosides are a class of antibiotics used to treat various bacterial infections. Clinicians must determine the elimination rate constant (k) and volume of distribution (VD) to optimize therapeutic efficacy and minimize toxicity. The k value represents the rate at which the drug is removed from the body, and the VD reflects the degree to which the drug distributes into body tissues. Accurately estimating these parameters allows healthcare professionals to tailor drug dosing to individual...
01:28Diphtheria
Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
01:23Inhibitors of Gram-positive Cell Wall Synthesis
Bacterial cell walls are typically rigid structures composed mainly of peptidoglycan, a mesh-like polymer that provides mechanical strength and maintains cell shape. The synthesis of peptidoglycan is a crucial process in bacterial growth and serves as a primary target for many antibiotics.Mechanism of Action of Beta-Lactam AntibioticsBeta-lactam antibiotics, such as penicillin, inhibit peptidoglycan synthesis in actively growing cells. These antibiotics share a characteristic four-membered...
01:25Inhibitors of Bacterial Protein Synthesis
Aminoglycosides constitute a highly potent class of bactericidal antibiotics that exert their antimicrobial effects by targeting the bacterial ribosome, specifically disrupting protein synthesis. These polycationic molecules consist of amino-modified sugars linked via glycosidic bonds to an aminocyclitol core such as 2-deoxystreptamine or streptamine. Their strong positive charges facilitate tight binding to the negatively charged phosphate backbone of ribosomal RNA (rRNA), primarily at the 16S...
01:25Clinical Significance of Antibiotic Resistance
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...